CMFRI, Library (2017) CMFRI develops anti-obesity medicine from marine organism Business Standard dated 16th February 2017. Business Standard.
Kochi-headquartered Central Marine Fisheries Research Institute (CMFRI) has developed an anti-obesity nutraceutical from seaweeds, the institute said on Wednesday. Kerala Governor Justice P Sathasivam will release the product during the CMFRI Platinum Jubilee celebrations inaugural function on Saturday, it said in a statement. CMFRI scientists prepared the product named CadalminTM Antihypercholesterolemic extract (CadalminTM ACe) from seaweeds which are commonly available in the Indian coastal waters and are known for their extraordinary medicinal properties. Kajal Chakraborty, Senior Scientist in Marine Biotechnology Division of CMFRI, who developed the product, said CadalminTM Antihypercholesterolemic extract can be administered to regulate clinical indicators leading to dyslipidemia or obesity, total adipose tissue and visceral fat, triglycerides besides cholesterol.
|Uncontrolled Keywords:||Newspaper; News; CMFRI in Media|
|Subjects:||CMFRI News Clippings|
|Divisions:||Library & Documentation|
|Depositing User:||Arun Surendran|
|Date Deposited:||16 Feb 2017 10:03|
|Last Modified:||16 Feb 2017 10:03|
Actions (login required)